// Biotech and Pharma Therapeutics
Chiesi partners with Wirral Primary Care to improve COPD detection
May 6, 2025 / hospital financial strategy / digital health tools / patient care access / vendor contract optimization / healthcare policy impact
Chiesi and Wirral Primary Care have launched COMET to enhance early COPD detection through community spirometry and rapid clinical management, aiming to reduce undiagnosed cases, prevent hospital admissions, and ease NHS respiratory care burdens.
Top Diabetes Companies in the Medical Device Industry
May 6, 2025 / diabetes devices market / continuous glucose monitors / top diabetes companies / glucose monitoring technology / medical device industry
The diabetes device market is projected to hit $44 billion by 2035, driven by the rapid adoption of continuous glucose monitors, with leading medical device companies shaping innovation and growth in diabetes care technology.
New predictive algorithms improve early detection of undiagnosed cancers
May 7, 2025 / early cancer detection / predictive cancer algorithms / undiagnosed liver cancer / NHS cancer screening / cancer risk prediction
Two new predictive algorithms developed from over 7.4 million NHS records enhance early cancer detection in primary care by integrating routine blood tests and clinical data, significantly improving the identification of undiagnosed cancers, including liver and oral cancers.
AI and Decentralized Trials: A New Era in Drug Development
May 7, 2025 / AI in clinical trials / decentralized clinical trials / remote patient monitoring / digital health innovation / drug development transformation
AI-powered decentralized clinical trials (DCTs) are revolutionizing drug development by improving patient access, enhancing data quality, and accelerating trial timelines through remote monitoring, wearables, and point-of-care testing—creating a more inclusive, efficient, and patient-centered research model.
The Patient Intake Revolution – How AI Is Eliminating Intake Busywork and Reducing Insurance Denials
May 7, 2025 / “AI in healthcare / patient intake automation / real-time insurance verification / reduce claim denials / healthcare workflow optimization
“
AI-driven automation is transforming patient intake by enabling real-time insurance verification, reducing administrative burden, cutting claim denials by up to 50%, and improving financial transparency—enhancing efficiency and patient experience in medical practices.
// 4th Industrial Revolution
AI Assistant Shows Promise in Easing Value-Based Care Burdens for Physicians, Study Finds
May 7, 2025 / AI heart screening pregnancy / maternal mortality prevention / AI ECG diagnostics / digital stethoscope cardiology / Mayo Clinic maternal health
A year-long study found that Navina’s AI Assistant significantly improves value-based care delivery by reducing physician burnout, streamlining documentation, and enhancing diagnostic accuracy, ultimately boosting RAF scores and Star ratings across participating primary care practices.
AI model significantly improves detection and treatment of delirium
May 7, 2025 / AI in delirium detection / hospital clinical decision support / Mount Sinai AI model / real-time risk stratification / delirium early intervention
An AI model developed at Mount Sinai quadrupled delirium detection rates in hospitalized patients by integrating real-time risk analysis and clinical workflows, enabling early intervention, safer prescribing, and reduced sedative use—marking a major advancement in hospital-based delirium care.
Wearable X-ray technology makes respiratory scans more comfortable for young children
May 6, 2025 / wearable X-ray technology / pediatric lung imaging / quantum dot detectors / low-radiation scans / child-friendly medical imaging
Researchers at the University of Queensland are developing a wearable, flexible X-ray imaging device using quantum dot technology to improve lung scans in young children—offering high-resolution, low-radiation imaging without the need for sedation or restraint.
Taiwanese AI company obtains 510(k) for video-based respiratory rate gauge
May 5, 2025 / AI respiratory monitoring / FDA 510(k) clearance / contactless vital signs / smartphone health tech / video-based health screening
FaceHeart, a Taiwanese AI firm, has received FDA 510(k) clearance for its contactless, video-based respiratory rate measurement software, which uses smartphone cameras and edge computing for secure, real-time vital sign monitoring across healthcare settings.
Harnessing generative AI to expand the mitochondrial targeting toolkit
May 5, 2025 / mitochondrial targeting sequences / generative AI in biology / synthetic biology tools / protein delivery systems / mitochondrial disease research
Researchers used generative AI to design novel mitochondrial targeting sequences (MTSs), overcoming current limitations in protein delivery for cellular studies and therapies. Their AI-generated MTSs showed high targeting accuracy across yeast, plant, and mammalian cells, enhancing opportunities in metabolic engineering and mitochondrial disease research.
// Business & Markets
Carta Healthcare raises $18.25M to expand AI clinical data platform
May 7, 2025 / AI clinical data platform / clinical trial recruitment AI / healthcare data abstraction / Carta Healthcare funding / real-time patient insights
Carta Healthcare raised $18.25M to expand its AI-powered clinical data abstraction platform, which streamlines trial recruitment, improves registry reporting, and delivers actionable insights from structured and unstructured data to support clinical efficiency and patient outcomes.
Masimo Sells Sound United for $350M
May 7, 2025 / Masimo Sound United sale / Masimo refocus healthcare / medical device divestiture / patient monitoring technology / Harman Samsung acquisition
Masimo has sold Sound United to Samsung’s Harman for $350M, exiting consumer electronics to refocus on its core healthcare business, particularly patient monitoring and medical innovation, following investor pressure and a leadership change.
Rula Health, Curai Health partner for mental health services
May 7, 2025 / Curai Health mental health / Rula Health partnership / virtual behavioral therapy / integrated primary care / AI-powered telehealth
Curai Health has partnered with Rula Health to expand access to integrated mental health services, enabling virtual primary care patients to connect with over 15,000 licensed behavioral health providers nationwide for coordinated, whole-person care.
Teva Pharmaceutical’s branded drugs boost first quarter profit
May 7, 2025 / Teva Pharmaceuticals earnings / Austedo Ajovy Uzedy sales / branded drug growth / Teva Q1 profit / Teva innovation strategy
Teva Pharmaceuticals reported strong Q1 profits driven by significant sales growth in its branded drugs for Huntington’s disease (Austedo), migraines (Ajovy), and schizophrenia (Uzedy), signaling successful innovation alongside its ongoing generics and biosimilars strategy.
PTC crashes as win for Novartis-partnered Huntington’s drug fails to convince investors
May 6, 2025 / PTC518 Huntington’s trial / Huntingtin protein reduction / PTC Novartis partnership / Huntington’s disease treatment / accelerated approval concerns
PTC Therapeutics’ Huntington’s drug PTC518 met its phase 2 biomarker endpoint by reducing Huntingtin protein levels, but mixed clinical signals and doubts about correlation with functional outcomes raised investor skepticism, casting uncertainty over accelerated approval prospects.
// Legal & Regulatory
Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy
May 5, 2025 / ATH434 Fast Track / Multiple System Atrophy treatment / Alterity Therapeutics MSA / FDA neurodegenerative drug approval / Phase 2 ATH434 trial
Alterity Therapeutics received FDA Fast Track designation for ATH434, a potential disease-modifying treatment for Multiple System Atrophy (MSA), based on Phase 2 efficacy and preclinical data. The designation accelerates development for this high-unmet-need neurodegenerative condition.
BioInvent Receives FDA Fast Track Designation for BI-1808 for the Treatment of Cutaneous T-Cell Lymphoma
April 29, 2025 / BI-1808 Fast Track / Cutaneous T-cell lymphoma treatment / BioInvent immunotherapy / anti-TNFR2 antibody / FDA designation CTCL
BioInvent’s BI-1808, a first-in-class anti-TNFR2 antibody, has received FDA Fast Track Designation for treating relapsed or refractory cutaneous T-cell lymphoma, including mycosis fungoides and Sézary syndrome, based on early signs of clinical efficacy and strong safety data.
FDA set to meet this month on COVID vaccines
May 7, 2025 / FDA COVID vaccine update / COVID booster variant 2024 / FDA vaccine advisory meeting / Vinay Prasad FDA appointment / Moderna COVID flu combo vaccine
The FDA will convene on May 22 to discuss updated COVID-19 vaccine formulations for the upcoming respiratory virus season, amid internal leadership changes and growing scrutiny over vaccine approval standards, potentially signaling stricter regulatory expectations moving forward.
Charles River Labs Stock Soars as Firm Shakes Up Board, Launches Review
May 7, 2025 / Charles River Laboratories / Board Restructure / Strategic Review / Medical Testing Industry / Elliott Investment Management
Charles River Laboratories announced a board restructuring and strategic business review under pressure from Elliott Investment Management, aiming to restore investor confidence and unlock shareholder value in the preclinical and medical testing sector.
Aldeyra posts one hit, one miss for twice-rejected dry eye drug, plans FDA filing
May 6, 2025 / Aldeyra Therapeutics / Reproxalap Trial Results / Dry Eye Disease Treatment / FDA Resubmission 2025 / Phase 3 Clinical Trials
Aldeyra Therapeutics’ dry eye candidate, reproxalap, met its primary endpoint in a phase 3 dry eye chamber trial. Despite a second trial missing significance, Aldeyra plans a 2025 FDA resubmission using supportive chamber and field data.
// Research & Development
Scientists map tongue’s sweet sensor, may lead to new ways to curb sugar cravings
May 7, 2025 / Sweet Taste Receptor / Sugar Cravings Research / Artificial Sweeteners / Cryo-EM Taste Study / Obesity and Diabetes Prevention
Columbia scientists have mapped the 3D structure of the human sweet taste receptor, revealing its binding pocket and paving the way for better sweetener design and potential interventions to curb sugar cravings and metabolic disorders like obesity and diabetes.
A culturally adapted obesity prevention for Latino families
May 7, 2025 / Latina Childhood Obesity / Culturally Adapted Intervention / Infant Feeding Practices / Public Health Prevention / Low-Income Latino Families
UC Riverside researchers adapted the Healthy Beginnings obesity prevention program to better serve Latina and low-income families by integrating culturally and linguistically relevant practices into early infant feeding education to reduce childhood obesity risk from infancy.
Researchers restore antibiotic effect in the event of resistance
May 7, 2025 / Antibiotic Resistance / Endolysin Therapy / Meningitis Treatment / Blood-Brain Barrier / Streptococcus Pneumoniae
Researchers at Karolinska Institutet demonstrated that combining endolysin with antibiotics restores effectiveness against resistant Streptococcus pneumoniae, including in the brain, offering a promising strategy for treating antibiotic-resistant meningitis and overcoming the blood-brain barrier challenge.
Sarepta tries to quell concerns over DMD gene therapy Elevidys as patients delay treatment after death report
May 7, 2025 / Duchenne Gene Therapy / Elevidys Safety Concerns / AAV Liver Toxicity / Sarepta Therapeutics Update / FDA Gene Therapy Review
Sarepta’s gene therapy Elevidys for Duchenne muscular dystrophy faces treatment delays after a patient death potentially linked to liver failure. Despite this, Sarepta maintains confidence in Elevidys’ long-term safety, efficacy, and continued regulatory support.
Sebela Pharmaceuticals Announces Positive Topline Results from Phase 3 TRIUMpH Program of Tegoprazan in GERD
April 29, 2025 / Tegoprazan GERD Treatment / Potassium-Competitive Acid Blocker / Erosive Esophagitis Healing / Rapid Acid Suppression / GERD Clinical Trial
Sebela Pharmaceuticals reported positive Phase 3 results for tegoprazan, a novel P-CAB, showing superior healing of erosive esophagitis and symptom relief in GERD patients versus lansoprazole, with rapid acid control and a favorable safety profile.
// Politics
Trump administration will defend FDA against abortion pill lawsuit, asks for dismissal
May 5, 2025 / Mifepristone Lawsuit / FDA Abortion Pill Defense / Medication Abortion Safety / Trump Administration DOJ / Abortion Pill Access
The Trump administration’s DOJ urged dismissal of a lawsuit seeking to restrict mifepristone, arguing red states lack jurisdiction and missed statutory deadlines. The FDA maintains mifepristone’s safety and efficacy for early medication abortion.
A Most Flawed Notion: Medicaid ‘Fix’ Will Worsen 340B Crisis
May 7, 2025 / 340B Drug Program / Medicaid Drug Pricing / Most Favored Nation Policy / Pharmaceutical Innovation Risk / Healthcare Cost Shifting
A proposed Medicaid “most favored nation” drug pricing policy could deepen 340B program distortions, reduce biopharma innovation, and shift healthcare costs to patients and private insurers—without directly benefiting underserved populations the programs were designed to help.
VA Secretary says he’s bullish on continued Oracle Health EHR rollout
May 7, 2025 / VA EHR Rollout / Oracle Health Implementation / Veterans Health Records / Electronic Health Record Modernization / VA IT Staffing Cuts
VA Secretary Doug Collins reaffirmed support for the Oracle Health EHR rollout, citing renewed oversight, internal restructuring, and a push for accountability from Oracle, despite concerns over staffing cuts and unresolved system issues at VA medical centers.
AdvaMed calls for ‘zero for zero’ medtech tariffs between US and UK
May 7, 2025 / Medtech Tariffs / FDA Device Approvals / U.S.-U.K. Trade / Healthtech Regulation / AdvaMed ABHI Proposal
AdvaMed and ABHI are urging the U.S. and U.K. to adopt a “zero for zero” tariff policy on medtech products and recognize FDA device approvals to prevent delays, protect healthcare systems, and ensure global access to medical innovations.
State attorneys general sue over ‘unconstitutional’ HHS restructuring
April 28, 2025 / HHS Restructuring Lawsuit / Maternal Health Cuts / Public Health Layoffs / Trump Administration Healthcare / State AGs Sue HHS
Twenty Democratic attorneys general are suing the Trump administration over mass layoffs at HHS, claiming the restructuring undermines federally mandated health programs like maternal care, addiction services, and disease monitoring, and violates constitutional and administrative law.